Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMXM7JR)

Drug Name
daminozide Drug Info
Synonyms DMASA; SADH; B 995; Alar; Kylar; B-NINE
Cross-matching ID
PubChem CID
15331
ChEBI ID
CHEMBL2164243
CAS Number
CAS 1596-84-5
TTD Drug ID
D0B2WZ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.26 0.00e+0 34/36 (94.44%) POLE2;RFC3;POLA2;...
Retrograde endocannabinoid signaling 2.01 9.42e-3 118/148 (79.73%) MAPK13;GRIA2;GNG11;...
Oxidative phosphorylation 1.99 1.26e-2 93/133 (69.92%) PPA2;ATP5F1D;ATP5ME;...
Proteasome 1.86 1.88e-2 44/46 (95.65%) PSMD6;POMP;PSME2;...
Base excision repair 1.83 1.88e-2 29/33 (87.88%) POLE2;POLD2;POLD4;...
Synthesis and degradation of ketone bodies 1.82 1.88e-2 9/10 (90%) OXCT1;ACAT2;BDH1
Bile secretion 1.78 2.29e-2 68/90 (75.56%) SLC4A4;CA2;UGT2B28;...
Fanconi anemia pathway 1.77 2.24e-2 36/54 (66.67%) CENPX;RAD51;FANCG;...
Drug metabolism 1.77 2.09e-2 78/151 (51.66%) UGT2B28;NME1;NME4;...
Pancreatic secretion 1.74 2.45e-2 87/102 (85.29%) PLA2G2A;SLC4A4;CA2;...
Parkinson disease 1.72 3.26e-2 176/249 (70.68%) UCHL1;ATP5F1D;TXN;...
Fat digestion and absorption 1.72 3.06e-2 35/43 (81.4%) PLA2G2A;ACAT2;PLPP1;...
Fatty acid degradation 1.71 3.04e-2 40/43 (93.02%) ACAT2;ADH5;GCDH;...
Cell cycle 1.69 3.30e-2 110/124 (88.71%) CDKN2A;CCND2;CDC20;...
Maturity onset diabetes of the young 1.69 3.20e-2 21/26 (80.77%) PAX6;HHEX;HES1;...
Pentose and glucuronate interconversions 1.68 3.24e-2 17/34 (50%) SORD;UGT2B28;UGT2A3;...
Valine, leucine and isoleucine degradation 1.67 3.66e-2 42/48 (87.5%) OXCT1;ACAT2;DLD;...
Pyrimidine metabolism 1.66 3.82e-2 40/56 (71.43%) TYMS;NME1;NME4;...
Butanoate metabolism 1.65 4.17e-2 23/28 (82.14%) OXCT1;ACAT2;BDH1;...
Homologous recombination 1.65 3.96e-2 35/41 (85.37%) RAD51;POLD2;POLD4;...
Ascorbate and aldarate metabolism 1.64 4.08e-2 15/30 (50%) UGT2B28;UGT2A3;UGT2B4;...
Glutathione metabolism 1.63 4.07e-2 43/57 (75.44%) LAP3;SRM;GSTA4;...
Diabetic cardiomyopathy 1.62 4.43e-2 162/203 (79.8%) MAPK13;COL1A1;ATP5F1D;...
PPAR signaling pathway 1.60 4.91e-2 66/74 (89.19%) DBI;FABP7;PLTP;...
alpha-Linolenic acid metabolism 1.57 4.93e-2 17/25 (68%) PLA2G2A;PLA2G12A;FADS2;...
Ferroptosis -1.93 2.12e-2 36/41 (87.8%) STEAP3;ACSL3;CP;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.04uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 20uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 20uM 24H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.04uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H